OCULIS HOLDING AG news, videos and press releases
For more news please use our advanced search feature.
OCULIS HOLDING AG - More news...
OCULIS HOLDING AG - More news...
- Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
- Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
- Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
- Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
- Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
- Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
- Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
- Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
- Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
- Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
- Oculis to Present at Upcoming March Investor Conference
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
- Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
- Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
- Oculis updates share capital for its existing at-the-market offering program
- Oculis Publishes Notification of Major Changes in Voting Rights
- Oculis Publishes Notification of Major Changes in Voting Rights
- Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
- Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
- Oculis Publishes Notification of Major Changes in Voting Rights
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
- Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities
- Oculis to Present at the Stifel 2024 Healthcare Conference
- Oculis to Present at the Stifel 2024 Healthcare Conference
- Oculis Reports Q3 2024 Financial Results and Provides Company Updates
- Oculis Reports Q3 2024 Financial Results and Provides Company Updates
